Cargando…

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease

BACKGROUND: Liver disease impacts on hepatic synthesis of lipoproteins and lipogenesis but data on dyslipidemia during disease progression are limited. We assessed the patterns of dyslipidemia in (i) different liver disease etiologies and discriminated (ii) non-advanced (non-ACLD) from advanced chro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unger, Lukas W., Forstner, Bernadette, Schneglberger, Stephan, Muckenhuber, Moritz, Eigenbauer, Ernst, Scheiner, Bernhard, Mandorfer, Mattias, Trauner, Michael, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748890/ https://www.ncbi.nlm.nih.gov/pubmed/31493100 http://dx.doi.org/10.1007/s00508-019-01544-5

Ejemplares similares

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease
por: Unger, Lukas W., et al.
Publicado: (2019)

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality
por: Unger, Lukas W., et al.
Publicado: (2019)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
por: Hartl, Lukas, et al.
Publicado: (2022)

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
por: Raeven, Pierre, et al.
Publicado: (2020)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2020)

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Letter to the Editor: Perioperative Presentation of COVID‐19 in a Liver Transplant Recipient
por: Reiberger,, Thomas, et al.
Publicado: (2021)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies
por: Königshofer, Philipp, et al.
Publicado: (2021)

Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
por: Bucsics, Theresa, et al.
Publicado: (2022)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_foh35129ib86cngdplb4h0hs3n